| Page 20 | CML Support

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive onco-kinases

Submitted by sandy craine on Fri, 20/06/2014 - 11:23am

F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1 "Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB-31121 did not inhibit activities of kinases including JFKs and SFKs and its exact mechanism of action is under investigation; however, it induced significant growth inhibition in a wide range of hematopoietic malignant cells. Investigation among various cell lines indicated that this compound was particularly effective against multiple myeloma and Burkitt lymphoma, and leukemia harboring BCR–ABL,

F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1

"Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB-31121 did not inhibit activities of kinases including JFKs and SFKs and its exact mechanism of action is under investigation; however, it induced significant growth inhibition in a wide range of hematopoietic malignant cells. Investigation among various cell lines indicated that this compound was particularly effective against multiple myeloma and Burkitt lymphoma, and leukemia harboring BCR–ABL,

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Submitted by sandy craine on Mon, 09/06/2014 - 1:49pm

Susan Branford1,*, David T. Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe Donaldson1, Mary Leong1, Linda Fletcher1, John F. Seymour3, Andrew P. Grigg4, David M. Ross5, and Timothy P. Hughes6

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Submitted by sandy craine on Thu, 15/05/2014 - 1:41pm

Carlo Gambacorti-Passerini,1 * Tim H. Brummendorf, 2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6

Carlo Gambacorti-Passerini,1
* Tim H. Brummendorf, 2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib

Submitted by sandy craine on Thu, 15/05/2014 - 12:46pm

L. Legros, J. Guilhot, S. Huault, F.X. Mahon, C. Preudhomme, F. Guilhot, A.O. Hueber, from the French CML Group (FI-LMC)

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

Submitted by sandy craine on Thu, 08/05/2014 - 2:38pm

David M. Ross1,2,3,4, Susan Branford5, John F. Seymour2,6, Anthony P. Schwarer2,7, Christopher Arthur2,8, David T. Yeung1,2,3, Phuong Dang1, Jarrad M. Goyne1, Cassandra Slader9, Robin J. Filshie2,10, Anthony K. Mills2,11, Junia V. Melo1,3, Deborah L. White1,2,3, Andrew P. Grigg2,12, and Timothy P. Hughes1,2,3

The impact of healthcare settings on survival time of patients with chronic myeloid leukemia Michael Lauseker

Submitted by sandy craine on Fri, 04/04/2014 - 12:45pm

Michael Lauseker1,Joerg Hasford1, Markus Pfirrmann1, and Rüdiger Hehlmann2 Key points * Chronic myeloid leukemia patients enjoyed superior survival chances when treated in teaching hospitals.

Michael Lauseker1,Joerg Hasford1, Markus Pfirrmann1, and Rüdiger Hehlmann2

Key points

* Chronic myeloid leukemia patients enjoyed superior survival chances when treated in teaching hospitals.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study

Submitted by sandy craine on Wed, 12/03/2014 - 3:39pm

Neil P. Shah1,*, François Guilhot2, Jorge E. Cortes3, Charles A. Schiffer4, Philipp le Coutre5, Tim H. Brümmendorf6, Hagop M. Kantarjian3, Andreas Hochhaus7, Philippe Rousselot8, Hesham Mohamed9, Diane Healey10, Michael Cunningham10, and Giuseppe Saglio11

Chronic Myeloid Leukemia: 2013 American Society of Hematology Annual Meeting*

Submitted by sandy craine on Tue, 04/03/2014 - 12:54pm

*Clinical Care Options: Oncology.

Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

Submitted by sandy craine on Tue, 11/02/2014 - 12:20pm

London, UK, January 09, 2014 -- The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSULIF® (bosutinib).

London, UK, January 09, 2014 --

The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSULIF® (bosutinib).

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Submitted by sandy craine on Fri, 31/01/2014 - 1:12pm

Michele Baccarani1, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-Hansen10, Timothy P. Hughes11, Hagop M. Kantarjian8, Dong-Wook Kim12, Richard A. Larson13, Jeffrey H. Lipton14, François-Xavier Mahon15, Giovanni Martinelli3, Jiri Mayer16, Martin C. Müller17, Dietger Niederwieser18, Fabrizio Pane19, Jerald P. Radich20, Philippe Rousselot21, Giuseppe Saglio22, Susanne Saußele17, Charles Schiffer23, Richard Silver24, Bengt Simonsson25, Juan-Luis Steegmann26, John M. Goldman27, and Rüdiger Hehlmann17

You are here